The TSX Venture Exchange has accepted for filing a share purchase agreement dated July 17, 2018, between Emerald Health Therapeutics Inc. and Abattis Bioceuticals Corp., whereby the company will acquire the remaining 40-per-cent interest in Northern Vine Canada Inc. held by Abbatis. Consideration is $2-million cash, 1,093,938 shares and, pursuant to certain milestones, additional shares of the company with an aggregate deemed value of $4-million. The shares are subject to a floor price that is not less than the discounted market price as of the date of the announcement (or $2.28). Any waiver of the floor price will be subject further exchange review and acceptance.

For more information, please see the news release dated July 19, 2018.